Filing Details
- Accession Number:
- 0001127602-23-026027
- Form Type:
- 4
- Zero Holdings:
- No
- Publication Time:
- 2023-10-17 18:50:49
- Reporting Period:
- 2023-10-16
- Accepted Time:
- 2023-10-17 18:50:49
- SEC Url:
- Form 4 Filing
Issuer
Cik | Name | Symbol | Sector (SIC) | IRS No |
---|---|---|---|---|
943819 | Resmed Inc | RMD | Surgical & Medical Instruments & Apparatus (3841) | 980152841 |
Insiders
Cik | Name | Reported Address | Insider Title | Director | Officer | Large Shareholder | Other |
---|---|---|---|---|---|---|---|
1485164 | J. Michael Farrell | Resmed Inc. 9001 Spectrum Center Blvd San Diego CA 92123 | Chief Executive Officer | No | Yes | No | No |
Reported Non-Derivative Transactions
Sec. Name | Acquisiton - Disposition | Date | Amount | Price | Remaning Holdings | Equity Swap Involved | Form Type | Code | Nature of Ownership | Explanation |
---|---|---|---|---|---|---|---|---|---|---|
Resmed Common Stock | Acquisiton | 2023-10-16 | 5,675 | $57.76 | 455,035 | No | 4 | M | Direct | |
Resmed Common Stock | Disposition | 2023-10-16 | 5,675 | $140.70 | 449,360 | No | 4 | S | Direct |
Equity Swap Involved | Form Type | Code | Nature of Ownership | Explanation |
---|---|---|---|---|
No | 4 | M | Direct | |
No | 4 | S | Direct |
Reported Derivative Transactions
Sec. Name | Sec. Type | Acquisiton - Disposition | Date | Amount | Price | Amount - 2 | Price - 2 |
---|---|---|---|---|---|---|---|
Resmed Common Stock | ResMed Common Stock Options | Disposition | 2023-10-16 | 5,675 | $0.00 | 5,675 | $57.76 |
Remaning Holdings | Exercise Date | Expiration Date | Equity Swap Involved | Transaction Form Type | Transaction Code | Nature of Ownership |
---|---|---|---|---|---|---|
9,140 | 2017-11-11 | 2023-11-16 | No | 4 | M | Direct |
Reported Non-Derivative Holdings
Sec. Name | Remaning Holdings | Nature of Ownership | Explanation |
---|---|---|---|
Resmed Common Stock | 0 | Indirect | Lisette and Michael Farrell Foundation |
Resmed Common Stock | 4,090 | Indirect | Lisette and Michael Farrell Family Trust |
Footnotes
- The transaction was conducted under a Rule 10b5-1 plan adopted November 8, 2021.
- This transaction was executed in multiple trades at prices ranging from $139.745 to 141.56. The price reported above reflects the weighted average sale price.
- Options are exercisable 1/3 each year beginning 1 year from date of grant.